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Abstract 
LADA is determined by both a noninsulin-dependent clinical presentation and an 
autoimmune pathogenic process. GADA constitutes the most important marker, although IA-
2A and ZnT8A also define LADA presentation. T2DM is the most prevalent type particularly 
over 65 years old. Studies about autoimmunity in this age group are scarce. 
Objective: The aim of this work was to determine whether three autoantibodies for diabetes 
autoimmunity were present in elderly T2DM patients, and to assess the distinctive clinical 
features of autoantibody-positive patients. 
Research Design and Methods: We recruited 153 patients with diabetes with onset of 
diabetes after 65 years of age and a BMI under 30 kg/m
2
  
Results: The prevalence of at least one of the autoantibodies was 15.68% (24/153). The most 
prevalent  autoantibody was GADA with 8.49% (13/153), followed by ZnT8A with 6.50% 
(10/153) and IA2A with 1.96% (3/153). The autoimmunity-positive group presented higher 
HbA1c (7.01±1.98 vs. 6.35±1.01; p=0.007) and more prevalent insulin therapy (25% vs. 
10.85%; p=0.047). GADA-positive patients with diabetes presented higher FPG (7.79 ± 3.79 
mmol/L vs. 6.43 ± 1.6 mmol/L ; p=0.014) and insulin therapy more frequently (46% vs. 
10.71%; p=0.015). GADA titer levels in the individuals with BMI under 27 kg/m
2
 were 
higher (35.00 ± 4.20) than those in the group with BMI over 27 kg/m2 (8.83 ± 3.041; 
p=0.0005). 
Conclusion: Autoantibodies GADA and Znt8A may be useful markers in identifying a 
subgroup of older patients with a clinical presentation of diabetes which could be 
characterized as latent autoimmune diabetes in the elderly . 
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Introduction 
Latent autoimmune diabetes in adults (LADA) is a complex and multifactorial clinical 
presentation of noninsulin-dependent diabetes mellitus, or type 2 diabetes mellitus (T2DM), 
determined by the loss of self-tolerance against endocrine pancreas β cells, a well-known 
pathogenic component of type 1 diabetes mellitus (T1DM) (1). LADA thus combines 
features of both T1DM and T2DM. As a matter of fact, whether LADA represents a different 
group from T1DM or is merely the same entity presented later in life is still under debate, 
although it has been suggested that this group is genetically, immunologically and clinically 
different from T1DM (2). 
Multiple factors are involved in the pathogenesis of LADA from genetics to clinical 
characteristics, including markers of autoimmune diabetes such as circulating autoantibodies, 
self-reactive T cells, evidence of lymphocytic infiltrates in β cells, non obesity, association 
with other autoimmune diseases and increasing insulin treatment, among others (3). Glutamic 
acid decarboxylase antibody (GADA) is a key marker of the autoimmune attack in LADA 
and by far the most common autoantibody in adult-onset diabetes (4). Several studies have 
determined other autoantibodies in LADA such as tyrosine phosphatase IA-2 antibodies (IA-
2A) and Zinc T8 antibodies (ZnT8A), although these markers have not been found in patients 
with T2DM (5-6). 
LADA patients are generally defined by onset >30 years of age, presence of circulating islet 
autoantibodies and no need of insulin treatment for 6 months after diagnosis (7). However, 
these patients need insulin earlier during diabetes progression than T2DM patients and are 
likely to respond poorly to oral antidiabetic drugs, although they may respond favorably to 
immunomodulatory therapy (8). To date, the largest cohort examined for LADA included 
over 6,000 adult-onset T2DM patients and revealed a prevalence of adult-onset autoimmune 
diabetes of 9.7% (9). As compared to T2DM patients, LADA patients generally present 
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earlier diabetes onset, lower body mass index (BMI) and a more pronounced loss of insulin 
secretion determined by lower C-peptide levels and hence increased insulin treatment (10). 
The LADA phenotype appears to vary in accordance with the GADA titer. GADA-positive 
patients with a high titer tend to have clinical characteristics resembling T1DM. These 
patients are younger and leaner at diagnosis, with a high risk of progression to insulin 
treatment. On the other hand, LADA patients with a low GADA titer are phenotypically more 
similar to those with T2DM. These differences are characterized by the presence of metabolic 
syndrome, which is more prevalent in T2DM than in T1DM or LADA (11-12-13).   
The TODAY Study evaluated GADA and IA2A in 1206 subjects between 10 and 17 years, 
clinically considered T2DM patients. Among the 118 patients (9.8%) found to be antibody-
positive, 71 (5.9%) were positive for a single antibody, while 47 were positive (3.9%) for 
both antibodies. This autoimmune process in Type 2 diabetes patients who are younger than 
Type 2 diabetes adults is referred to as latent autoimmune diabetes in the young (LADY).(14) 
The incidence of diabetes increases an overall 23% every year, while prevalence increases 
62% in patients 65 years and older (15). More than 20% of the population over 65 years of 
age suffer from diabetes; most of them have T2DM, while 0.3% women and 0.4% men 
between 60 and 80 years of age have T1DM (16). Pietropaolo et al. have reported GADA and 
IA-2A detection in 12% of 196 serum samples from phenotypically T2DM patients older 
than 65 years (17). However, no studies have been published determining ZnT8A in this 
T2DM patient age group. 
In this context, the main goal of our study was to determine whether the autoantibodies 
currently regarded to have predictive value for autoimmunity, i.e. GADA, IA2A and ZnT8A, 
were present in T2DM patients with onset over 65 years of age and a BMI under 30 kg/m
2
. 
The secondary aim was to compare the anthropometric, clinical and biochemical findings 
between patients with positive and negative autoantibodies. 
 
This article is protected by copyright. All rights reserved. 
 
Materials and Methods 
 Healthy Argentine control individuals 
Control sera were obtained from 125 healthy Argentine individuals (52% female) without 
personal or family history of diabetes mellitus or autoimmune diseases and normal fasting 
glucose. The sample collection was approved by the Ethics Committee of the José de San 
Martín Clinical Hospital, University of Buenos Aires (UBA), Buenos Aires, Argentina. All 
subjects were informed about the purpose of the study, and a signed consent for study 
participation was obtained. GADA, IA2A, ZnT8A and IAA were assessed, and all of the 




Argentine patients with diabetes  
This was a cross-sectional study which did not include a follow-up of the patients. The 
patients were recruited over one year, between July 2016 and August 2017, with the two 
inclusion criteria described below. All patients were receiving or had received treatment with 
oral drugs or insulin therapy targeting an A1c level under 7%, but received no further 
treatment as part of the study.  
We randomly recruited 153 T2DM patients (58% women) with the following inclusion 
criteria: individuals with diabetes onset over 65 years of age, without insulin treatment until 
12 months after diagnosis and BMI under 30 kg/m
2  
.The exclusion criteria were: patients 
with active systemic disorders and/or infections, individuals with a previous diagnosis of 
T1DM, liver or heart failure, surgery or hospitalization over the past year. The diagnosis of 
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diabetes was carried out in accordance with the guidelines of the American Diabetes 
Association (18). Written consent was obtained from all participants involved in this study. 
 
Measurements 
Anthropometric measurements (height, weight and waist circumference), systolic blood 
pressure and dyastolic blood pressure were determined by standardized protocols. BMI was 
calculated as weight (kg)/[height(m)]
2
. After a 12 h overnight fast, venous blood samples 
were obtained from every individual, centrifuged to obtain serum and analyzed immediately. 
Fasting plasma glucose (FPG), creatinine, total cholesterol, TG, LDL-C and HDL-C were 
determined in serum using standardized procedures by enzymatic methods. HbA1c was 
measured using high-performance liquid chromatography (HPLC) Variant II Turbo HbA1c 
Kit 2.0. 
All subjects underwent a detailed standard evaluation to detect diabetic retinopathy (fundus 
photography), and nephropathy was defined by microalbuminuria (at least two of three 
consecutive visits with an albumin excretion rate of 20 µg/min or higher). Cardiovascular 
disease was established with respect patients’ clinical records of coronary heart disease, 
stroke, or peripheral arterial disease. 
Ethics statement 
All procedures followed were in accordance with the ethical standards of the committee 
responsible for human experimentation (José de San Martín Clinical Hospital, University of 
Buenos Aires, UBA) and with the Helsinki Declaration of 1975, as revised in 2008. 
Radioligand binding assay protocol for GADA, IA2A and ZnT8A 
GADA, IA2A and ZnT8A were assessed by radioligand binding assay (RBA) as previously 
described (6). Briefly, 5 uL human sera were incubated overnight at 4ºC with 10,000 cpm of 
[35S]-ZnT8-Arg–Trp325, [35S]-GAD65 or [35S]-IA2A, respectively, in a final volume of 60 
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uL in the RBA buffer. Afterwards, 50 uL protein A-Sepharose 4B FF (GE Healthcare 
Biosciences, Uppsala, Sweden) was added in the RBA buffer (2:3) to isolate 
immunocomplexes and incubated for 2 h at room temperature on an end-over-end shaker. 
Subsequently, samples were allowed to settle and the supernatants were discarded. Pellets 
were washed three times with 200uL RBA buffer and once with 200 uL of 0.2 M NaCl in 
RBA buffer. Finally, pellets were suspended in 100 uL of 1% w/v SDS and supernatants were 
carefully transferred to vials for scintillation counting (1 min per tube). Results for each 
sample were calculated as bound % (B%)=100 x (bound cpm/total cpm), and expressed as 
standard deviation scores (SDs)=(B%-Bc%)/SDc, where Bc% is the mean B% of control sera 
and SDc its standard deviation. Thirty normal control sera were included in each assay and 
Bc% was normally distributed. An assay was considered positive when SDs > 3. In the 
Diabetes Antibody Standardization Program (DASP) 2007, our GADA assay proved to have 
79.6% sensitivity and 98.0% specificity. Likewise, in the Islet Autoantibody Standardization 
Program (IASP) 2015, our IA-2A assay had 66.0 % sensitivity and 97.8% specificity, while 
our ZnT8A assay showed 68.0% sensitivity and 97.8% specificity. 
We established an arbitrarily high or low level of GADA considering whether the titer was 
above or under 20 SDs, respectively. 
Statistical analysis 
Data on continuous variables are shown as means ± SDs. Categorical variables are reported 
as proportions (%). A two-tailed probability value of 0.05 was considered to be statistically 
significant. Odds ratios (ORs) are reported with their 95% confidence intervals (CIs). The 
D'Agostino and Pearson omnibus normality test was applied to assess whether data from 
normal human control sera were normally distributed. The Mann–Whitney U test was used to 
evaluate significant differences in SDs. For univariate analysis, differences between groups 
for qualitative variables were assessed by Fisher’s exact test. One-way ANOVA was 
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conducted for comparisons of continuous variables and Levine’s test was performed to study 
equality of variances. Variables that appeared to be associated in the univariate analysis were 
introduced into the multivariate analysis. Multiple linear regression and logistic regression 
analyses were used to adjust for possible confounding variables. Statistical analyses were 
conducted using Statistical Package for the Social Sciences software, version 12.0 (SPSS, 





The prevalence of the three positive autoantibodies was 15.68%, including 24 out of 153 
T2DM patients recruited. Among the 153 patients evaluated, GADA autoantibody exceeded 
the cutoff point in 8.49% cases (13/153), IA2A in 1.96% (3/153) and ZnT8A in 6.50% 
(10/153). Among the patients with autoimmune diabetes, GADA was the most prevalent 
autoantibody with 58.29% (13/24), Znt8A was present in 41.66 % (10/24) and IA2A in 
12.5% (3/24). Only two patients presented positivity for two antibodies simultaneously: one 
of them GADA and IA2A, and the other one GADA and ZnT8A (Figure 1). 
The comparison between autoimmunity-positive and negative patients revealed statistically 
significant differences with respect to sex, as women accounted for 75% of autoantibody-
positive subjects but only 54.2% of the antibody-negative group (p=0.046). In contrast, no 
significant differences were detected in terms of BMI, age, age at diagnosis or duration of 
disease regarding the presence or absence of islet autoantibodies. The analysis of HbA1c 
levels also rendered significant differences, as 56.52% (13/23) autoimmunity-positive 
subjects exceeded HbA1c of 7% (53.01 mmol/mol) regarded as a metabolic control cutoff, as 
compared to 22.83% (29/127) subjects in the autoimmunity-negative group (p=0.038). In this 
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way, the autoimmunity-positive group presented worse metabolic control measured by 
HbA1c than the autoimmunity-negative group (7.01± 1.98 vs. 6.35± 1.01, p=0.007). On the 
other hand, FPG in the autoimmunity-positive group was higher, though not statistically 
different from that observed in the autoimmunity-negative group (Table 1). 
In agreement with worse metabolic conditions, more autoimmunity-positive patients received 
insulin treatment (25%) as compared to autoimmunity-negative subjects (10.85%; p=0.047). 
These results were sex-adjusted with a considerably elevated OR of 3.097 (1.01-9.42% CI), 
which reinforced the relevance of insulin treatment for autoimmunity-positive patients with 
the evolution of diabetes. No statistical differences were found between groups with respect 
to treatment with antidiabetic oral drugs (Table 2). 
No differences were detected between groups regarding T2DM comorbidities such as obesity, 
hypertension and metabolic syndrome, or microangiopathic complications such as 
nephropathy and retinopathy (Table 3). 
GADA-positive T2DM patients presented higher levels of FPG (7.79 ± 3.79 mmol/L) as 
compared to GADA-negative ones (6.43 ± 1.6 mmol/L; p=0.014). Also, in accordance with 
the worse metabolic control, the GADA-positive T2DM group rendered a larger proportion 
of insulin treatment cases (5/13, 38.46%) than the GADA-negative T2DM group (15/140, 
10.71%; p=0.015) with a remarkably high OR of 8.208 (1.509-17.981; 95% CI). 
The analysis of GADA levels revealed statistical differences regarding the high-GADA titer 
group, which accounted for a large proportion of the BMI < 27 kg/m
2
 group (6/7 patients, 
85.7%) but no cases in the BMI > 27 kg/m
2
 group (0/6, 0%; p=0.004). Finally, assays on 
GADA levels as a continuous variable rendered a GADA titer of 35.00 SDs ± 4.20 in BMI < 
27 kg/m
2 
individuals, which was significantly different from the GADA titer of 8.83 ± 3.041 
in the BMI > 27 kg/m
2 
group (p=0.0005) (Figure 2). 
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Discussion 
Diabetes is known to have major impact on the health of elderly patients, which makes it 
essential to implement appropriate treatment based on its clinical and pathophysiological 
presentation (19). Still today, clinical practice with  over 65 patients with diabetes involves 
the pathophysiological interpretation, the metabolic changes and the treatment strategies used 
in younger patients. 
This study constitutes a first report on the presence of the three antibodies against β cells 
currently used in diagnosis, i.e. GADA, IA2A and ZnT8A, in a population of elderly T2DM 
or non-insulin-dependent diabetes mellitus patients, diagnosed over 65 years of age and 
exhibiting normal weight or slight overweight. To the best of our knowledge, no previous 
studies have been conducted on ZnT8 in elderly T2DM patients, and most trials about the 
prevalence of autoimmunity in adult diabetes range from 30- to 70-year-old patients. 
Moreover, this study provides evidence of autoimmunity in a scarcely documented 
population, i.e. non-obese patients with diabetes. In 1999, an Italian population composed of 
lean, BMI < 25%, newly diagnosed patients between 30-54 years old was studied in order to 
determine the prevalence of islet β cell antibodies (ICA) and GADA. Among 130 patients 
recruited, 34.6 % were ICA-positive, 22.3% were GADA-positive, and almost 50% presented 
slowly progressive autoimmune diabetes (20). In addition, previous studies by our group have 
analyzed the presence of proinsulin autoantibody (PAA), GADA, IA2A and ZnT8 in 
271 patients diagnosed with diabetes at mean age 53.4 ± 10.9, BMI ≤ 30, without insulin 
treatment for the first year of disease. Among them, 22.1% presented at least one humoral 
marker, 2.6% were PAA+, 12.5% were GADA+, 3.3% were IA-2A+, and 10.7% were 
ZnT8A+ (6). 
In the current study, we observed a high prevalence of autoimmunity in older patients with 
diabetes, as 15.68% of them tested positive for at least one antibody.  The most prevalent 
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autoantibody was GADA with 8.49%, followed by ZnT8A with 6.50%, in agreement with 
previous reports on autoimmunity in T2DM patients. In this sense, it has been demonstrated 
that ZnT8A is, in fact, a helpful humoral marker that should be included in diagnostic tests 
for the screening of LADA. Previous reports have proven that patients with adult-onset 
diabetes mellitus, initially identified as marker-negative based on GADA and IA-2A 
screening, were reclassified as autoantibody-positive when tested for ZnT8A. On the other 
hand, in non-obese, adult-onset patients with diabetes the use of a dimeric construct (C-
terminal domain of ZnT8 -amino acids 268–369- carrying Arg325–Trp325) showed the 
highest percentage of autoimmunity detection. It is reasonable to think that the increase in 
assay sensitivity may be due to an increased functional avidity of specific antibodies for these 
best structured antigenic variant (6, 21).   
Only 2 patients proved positive for two simultaneous antibodies, GADA and IA2A in one 
case, and GADA and ZnT8A in the other one. As expected in cases of late autoimmunity 
presentation, no patients presented three antibodies. Our study also shows women to be more 
affected by autoimmunity than men, in agreement with several studies showing women 
susceptibility to autoimmune diseases (7, 22). 
The largest cohort studied so far involved a European population of 6,156 T2DM patients in 
which 9.75% patients were found to be autoimmunity-positive. Regarding specific antibody 
expression, 541 (8.8%) were GADA-positive and only 57 (0.9%) were IA-2A or ZnT8A-
positive (7). In turn, the U.K. Prospective Diabetes Study (UKPDS), which included mainly 
overweight patients, focused on ICA and GADA in a group of newly diagnosed patients 
ranging between 35 and 54 years of age. In this case, 12.5% patients were positive for at least 
one antibody, with 6.5% ICA-positive and 10.7% GADA- positive patients, and only 4.6% 
two-antibody-positive (23).  
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On the other hand, a report from Pittsburgh about the prevalence of GAD 65AA analyzed a 
sample of 3,318 adults 65 years or older included in the Cardiovascular Health Study. The 
individuals were classified into five groups: 1) known diabetes, 2) newly diagnosed diabetes, 
3) impaired glucose tolerance only, 4) impaired fasting glucose and 5) controls. The 
prevalence of GADA was 5.3%, 2.2%, 1.9%, 2% and 1.8%, respectively. The prevalence of 
GADA was statistically higher in participants diagnosed with diabetes compared to 
normoglycemic controls and increased with decreasing glucose tolerance.. GADA positivity 
in this elderly population was associated with diagnosed diabetes and the use of insulin and 
oral drugs combined. In this work, the authors studied the overall population of T2DM 
patients over 65 years old and found, in agreement with our results, that GADA-positive 
T2DM patients used insulin treatment more frequently (24). 
A Swedish study on newly diagnosed patients over 65 showed a high 15% prevalence of 
GADA among 231 patients.  Of 20 patients, 5 (25%) with two or three antibodies were 65 
years of age or older at diagnosis, and 4 of 5 (80%) had developed complete β-cell failure 
after 12 years. (25)  
Recently, the LADA China Study published research on 529 non-insulin-requiring patients 
with diabetes over 30 years old with positive autoantibodies GADA or IA2A. Those LADA 
patients were separated in two groups in accordance with the onset of diabetes over or under 
60 years of age, LADA-Elderly and LADA-Young, respectively. LADA-E compared with 
LADA-Y had better residual β-cell function, higher insulin resistance, more serious 
metabolic syndrome characteristics, similar proportion of islet autoantibody positivity and, 
strikingly, different HLA-DQ genetic background (26).   
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On the other hand, it is worth pointing out that the discrepancy observed in the prevalence of 
GADA across different studies may be due to differences in recruitment criteria, genetic 
background, ethnic origin and BMI, among other factors. However, GADA is unequivocally 
the most prevalent antibody generally observed. 
The present study shows ZnT8A as the second most prevalent antibody, with a high 6.50% in 
this particular population of autoimmune diabetes over 65 years of age. Our group had 
previously determined ZnT8A positivity in another cohort of Argentine patients, which 
rendered 29 (10.3%) ZnT8-positive cases out of 282 non-obese adult patients with diabetes 
(27). Furthermore, the NIRAD study analyzed ZnT8A in 196 patients with adult onset 
autoimmune diabetes (ADA) previously known to be GADA or IA-2A-positive, with results 
showing 18.6% ZnT8A detection (21). This recently discovered antibody may thus be 
regarded as extremely useful in the diagnosis of ADA, being second to GADA in prevalence 
among both adult and elderly patients with diabetes. 
Zampetti et al. found that the presence of ZnT8 antibodies was more frequent in LADA 
patients with high GADA titer compared with LADA patients with low GADA titer and type 
2 diabetes patients. These authors also found a high prevalence of other autoantibodies in 
LADA patients with high LADA titer such as thyroid peroxidase, steroid 21-hydroxylase, 
tissue transglutaminase and antiparietal cell antibodies.(28)  
The present work also shows worse metabolic conditions among autoimmunity-positive 
patients with diabetes considering < 7% HbA1c levels a good metabolic control, as 
established by the American Diabetes Association (19). In this regard, GADA-positive 
T2DM patients presented higher levels of both FPG and HbA1c as compared to GADA-
negative patients, which confirms the metabolic alterations associated to autoimmunity. 
Along the same line, a recent retrospective study in a Swedish population showing a 107-
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month follow-up of 372 GADA-positive LADA patients revealed worse metabolic conditions 
than those of early diagnosed T2DM patients (29). 
The current study further found that patients with autoimmunity had higher insulin 
requirements than those without autoimmunity. Multiple studies have found that LADA 
patients require insulin treatment more frequently and earlier than those with antibody-
negative T2DM. In the HUNT study, 40% GADA-positive patients vs. 22% GADA-negative 
patients received insulin treatment 14 years after diagnosis. (30).  
In the CARDS report, 56% and 17% of GADA-positive and negative patients, respectively, 
required insulin at the beginning of the study. In addition, during a 45-month follow-up, 16% 
LADA patients needed insulin treatment, as opposed to 5% among those with non-
autoimmune T2DM (31). Taken together, these findings suggest that the proper identification 
of autoimmunity in elderly T2DM patients may facilitate the implementation of earlier 
insulin treatment. 
The present work also shows that, among patients with autoimmunity, those with a high 
GADA titer were leaner than those with a low GADA titer. As expected, no differences were 
found regarding metabolic syndrome between low and high-GADA-titer patients, although it 
should be considered that our population was recruited with a BMI below 30%. In line with 
these results, several reports have shown high-GADA-titer patients to share some clinical 
characteristics to T1DM, such as earlier diagnosis, lower BMI and lower risk of progression 
to insulin treatment. In contrast, low-GADA-titer patients are phenotypically more similar to 
those suffering T2DM, with clinical characteristics resembling metabolic syndrome and 
insulin resistance (31, 32, 33).  
Even if the seemingly small number of T2DM patients with positive autoimmunity  may be 
thought of as a weakness of the present study, proper considerations should be made as to the 
specific characteristics of the cohort and the fact that the prevalence of autoimmunity in the 
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entire population of elderly T2DM patients remains unknown. In addition, it is important to 
recognize the presence of autoimmunity as a means to attain optimal metabolic control and 
preserve β-cell function to decrease the risk of long-term diabetes complications. In this 
regard, recent progress has been made through specific treatment with dipeptidyl peptidase 4 
inhibitors to protect C-peptide levels and improve glycemic control in LADA patients (34, 
35). 
In summary, the findings reported here support the use of GADA and Znt8A as two key 
markers in identifying a subgroup of elderly patients whose condition may be referred to as 
latent autoimmune diabetes in the elderly, with a clinical presentation resembling that of 
T2DM, albeit with worse metabolic control and a higher need of insulin treatment. In this 
regard, GADA and Znt8A determination may shed light on the adequate classification and 
treatment of autoinmmunity in elderly patients and the mechanisms involved in autoimmune 
diabetes. The present work thus contributes to a better understanding of diabetes in the 
elderly and to the implementation of healthcare practices which better match their recognized 
age-related weakness. 
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Table 1 Clinical characteristics of the sample 
Variable          Without autoimmunity With autoimmunity    Total                p value 
  (n=129)  (n=24)  (n=153)  
Sex (women/men) 70/59  18/6  88/65  0.046 
Age (yr)  77.48±6.25 76.83±5.30 77,32±6,16 0.653 
Weight (kg) 66.47±12.26 64.14±8.38 66,11±11,75 0.375 
BMI (kg/m2) 25.62±2.60 25.88±2.30 25.68±2.54 0.636 
WC (cm)  92.50±10.41 93.95±12.85 92,83±10,76 0.545 
WC (cm) (women) 88.91±9.61 91.63±12.37 89.49±10.24 0.307 
WC (cm) (men) 96.76±9.76 101.00±11.42 97.15±9.90 0.322 
FPG (mmol/L) 6.45 ± 1.63 7.04 ± 3.03 6.54 ± 1.90 0.172 
HbA1c (%,  6.35 ± 1.01 7.01 ± 1.98 6.47 ± 1.22 0.007* 
mmol/mol ) 45±11         53± 2                   47± 3  
TC (mmol/L) 4.80 ± 0.96 5.13 ± 1.11 4.85 ± 0.99 0.158 
HDL-C (mmol/L) 1.28 ± 0.28 1.36 ± 0.38 1.29 ± 0.30 0.222 
LDL-C (mmol/L) 2.94 ± 0.82 3.10 ± 1.05 2.96 ± 0.85 0.421 
TG (mmol/L) 1.35 ± 0.57 1.55 ± 0.75 1.38 ± 0.6  0.155 
Creatinine (µmol/L) 97.24 ± 37.12 91.93 ± 23.86 96.35 ± 35.36 0.52 
C-peptide (ng/mL) 0.52 ± 0.25 0.48 ± 0.24 0.51 ± 0.25 0.515 
 
 
BMI, Body mass index; WC, waist circumference; FPG, fasting plasma glucose; HbA1c, glycated hemoglobin; TC, total cholesterol; HDL-
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Table 2. Treatment with insulin and antidiabetic oral drugs  












MTF  NO 51 (39.53) 10 (41.66) 0.915 (0.378-2.218) 0.601 
 YES 78 (60.46) 14 (58.33)   
Sulph NO 100 (77.5) 19 (79.16) 0.907 (0.312-2.641) 0.883 
 YES 29 (22.5) 5 (20.83)   
INS
  
NO 115 (89.14) 18 (75.0) 2.738 (0.932-8.044) 0.047* 
 YES 14 (10.85) 6 (25.0)   
  (n =129 ) (n = 24)   
Treatment: MTF, metformin; Sulph, sulphonylurea; INS, insulin. pa  adjusted by sex 
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Table 3. Comorbidities and chronic complications with and without autoimmunity 










MS NO 49 (37.98) 8 (33.330) 1.225 (0.488-3.074) 0.425 
 YES 80 (62.02) 16(66.66)   
HT  NO 27 (18.00) 4(37.5) 1.235 (0.377-4.041) 0.491 
 YES 82(82.00) 15(62.5)   
Retinopathy NO 118 (91.47) 19(79.16) 2.823 (0.882-9.031) 0.081 
 YES 11(8.52) 5(20.83)   
Nephropathy NO 102(79.06) 20(83.34) 0.756 (0.238-2.396) 0.436 
 YES 27(20.93) 4(16.66)   
CV  NO 94(72.87) 22(91.67) 0.244 (0.055-1.093) 0.036* 
 YES 35 (27.13) 2(8.33)   
HyT  NO 108 (83.72) 17 (70.83) 2.118 (0.782-5.737) 0. 115 
 YES 21 (16.27) 7 (29.16)   
  (n =129 ) (n = 24)   
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